Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases, today ...

The Task Force of the European Academy of Neurology and the Peripheral Nerve Society published updated guidelines in 2024 on the diagnosis and treatment of Guillain ... if the patient is unable ...

Hansa Biopharma AB, "Hansa" (Nasdaq Stockholm: HNSA), will present data from its 15-HMedIdeS-09 Phase 2 single arm study of imlifidase, a first in class IgG cleaving enzyme, in Guillain-Barré Syndrome ...

According to mayoclinic.org, Guillain-Barré patients often experience numbness or paralysis that can quickly spread throughout the body. At that point, Bergstrom’s lacrosse future was in doubt ...

The Move GBS Forward campaign highlights a promising new approach to treatment of the disease. Annexon Biosciences CEO Doug ...

The GBS | CIDP Foundation International is commemorating Guillain-Barré Syndrome and Chronic Inflammatory Demyelinating Polyneuropathy Awareness Month this May by launching a global campaign to raise ...

The technology has gradually helped Maynard get closer to her ultimate goal — reaching total independence and returning to ...

--(BUSINESS WIRE)--Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable ...

Peruvian authorities Saturday declared a 90-day nationwide sanitary emergency due to the “unusual increase” in cases of Guillain-Barré ... allocated to improving patient care, reinforcing ...

Guillain-Barré syndrome (GBS ... despite this therapy, some patients still make a slow or incomplete recovery. A recent study (Kuitwaard et al, 2009) aimed to examine whether pharmacokinetics ...

A Nottingham mechanic who was paralysed from the face down and had to sleep with his eyes open for three weeks has thanked ...